U.S. Life Sciences Stock News

As U.S. markets navigate record highs with the Nasdaq and S&P 500 leading the charge, investors are keenly watching the Federal Reserve's upcoming interest rate decision, which could influence future market dynamics. In this environment of heightened anticipation and economic shifts, dividend stocks offer a compelling opportunity for those seeking steady income amid potential market volatility.

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...

When close to half the companies in the Commercial Services industry in the United States have price-to-sales ratios...

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Earlier this month, Science Applications International Corporation (SAIC) lowered its fiscal 2026 revenue guidance to a range of US$7.25 billion to US$7.33 billion, signaling weaker organic revenue with projected declines of 5.5% and 4% for the third and fourth quarters, respectively. This cautious outlook comes despite a recent management reshuffle and ongoing share repurchases, highlighting the challenges SAIC faces in stabilizing its top-line growth amid a shifting government IT...

Earlier this month, Mid-America Apartment Communities presented at the BofA Securities 2025 Global Real Estate Conference in New York, where key executives detailed the company's focus on high-demand Sunbelt and southwestern markets, as well as their confidence in stable occupancy and growth prospects. An important insight emphasized by management was the expectation that continued migration trends and housing affordability challenges will support sustained apartment demand and position the...

Carnegie Mellon University and BNY Mellon recently announced a five-year, US$10 million partnership to launch the BNY AI Lab, which will drive artificial intelligence research, talent development, and industry collaboration with a dedicated facility on CMU’s Pittsburgh campus. This collaboration not only targets advanced AI solutions for financial services but also places BNY Mellon in a unique position to recruit top AI talent and shape the governance of emerging technologies in its...

If you have been watching the energy sector, you have probably noticed Valero Energy popping up on more investors’ radars lately. Maybe you are trying to decide if now is the moment to get in, take profits, or just keep riding along with the momentum. Let’s talk it through. Over the past year, Valero has jumped by 21.0%, and that is just a slice of the story. Over the last five years, the stock has ballooned a massive 301.6%. Even more striking, Valero has gained 14.6% in the past month alone...

CRISPR Therapeutics AG recently presented encouraging clinical and commercial updates at major industry conferences in New York, featuring new data on its in vivo gene-editing pipeline and expanding adoption of its Casgevy therapy. The company’s progress across cardiovascular, oncology, and autoimmune programs highlights an ambition to extend its gene-editing technology beyond blood disorders. We’ll examine how the promising early CTX310 trial data shapes CRISPR Therapeutics’ investment...

If you have been eyeing Snap’s stock and wondering whether it finally deserves a spot in your portfolio, you are not alone. The ride has not been for the faint-hearted. After peaking a few years back, Snap’s price treaded downward, with a staggering 69.3% drop over five years and a 34.7% dip year-to-date. Even its one-year return sits at -23.9%, a reminder that long-term buy-and-hold investors have faced tough sledding. However, the story gets more interesting when you look at the recent...

Constellium (NYSE:CSTM) just made headlines with its announcement to extend a long-term partnership with Embraer, one of the heavyweights in global aviation. This deal will see Constellium continuing to supply high-performance aluminum solutions, including its advanced Airware alloy, across Embraer’s commercial, executive, and defense divisions. For investors, this agreement signals more than a continuity plan. It could be a sign that Constellium's products are increasingly indispensable to...

If you have Lithia Motors on your watchlist, you are probably wondering whether now is the right time to make a move. After all, the stock has proven it can deliver impressive gains, surging nearly 20% over the past year and climbing an eye-catching 54.7% across five years. But it is not all up and to the right. More recently, the shares are down a modest 1.6% in the last week, while bouncing back 11.0% over the past month. Year-to-date, the story is more mixed, with the stock down 4.2%. This...

ANI Pharmaceuticals (ANIP) has just turned heads with its latest announcement, projecting 2025 revenues in the range of $818 million to $843 million. That’s a jump of 33% to 37% over last year, a confident call from management that’s tough to ignore if you’re weighing your next move. This new guidance seems to have struck a chord with the market, and it’s no surprise; bold forecasts often get investors reassessing what the company might be worth. The positive momentum was already in motion...

In recent days, Inter Milan announced a significant leadership change with Cristian Chivu taking over as manager, alongside a strategic pivot toward recruiting younger players supported by enhanced financial stability under new ownership. This transition has not only signaled a long-term vision for talent development, but has also resulted in Inter surpassing Juventus in enterprise value amid ongoing efforts to strengthen its balance sheet and competitiveness in Serie A. We'll take a look...

In recent days, the Independent Development Trust (IDT) has come under renewed scrutiny following allegations of corruption involving suspended CEO Tebogo Malaka, including accusations of attempted bribery of a journalist and procurement irregularities linked to an R800 million oxygen plant project. This high-profile probe has triggered criticism of political interference and prompted the appointment of PwC to conduct an independent investigation, highlighting concerns around governance and...

Earlier this month, Honeywell International announced a US$600 million equity raise for its quantum computing subsidiary Quantinuum, valuing the business at US$10 billion pre-money, with funds aimed at advancing its next-generation Helio quantum computer and expanding global AI and scientific partnerships. This significant move highlights Honeywell’s deepening push into high-potential quantum and artificial intelligence markets, positioning Quantinuum for accelerated innovation and future...

Reddit recently reported strong quarterly results, marked by significant year-over-year revenue growth and its first-ever GAAP profitability, drawing notable attention from market participants. This period has also seen a surge in analyst optimism and institutional investor interest, even as concerns around valuation and sustainability remain prevalent. We'll explore how Reddit's first GAAP-profitable quarter and rapid revenue growth influence the company's long-term investment...

Brown & Brown (BRO) just made a move that’s got investors leaning in. COO Steve Hearn has been tapped to take charge of all operations outside North America, spanning the Retail and Specialty Distribution segments. Executive shifts like this might sound like a simple org chart update, but for a company eyeing global growth, putting a seasoned leader at the international helm could signal bigger ambitions or a fresh approach to global strategy. It’s a reminder that even subtle changes at the...

If you’re wondering what to make of Progyny (PGNY) after this week’s news, you’re not alone. The company just announced that Fellow Health will join its network, giving eligible members access to mail-in semen analysis kits processed by CLIA-accredited labs. The goal is to break down barriers in fertility care by making at-home, privacy-oriented testing both convenient and clinically robust. This move directly addresses the widespread but too-often-overlooked challenge of male factor...

Earlier this month, Pulse Biosciences announced that the U.S. FDA approved its Investigational Device Exemption, allowing the company to begin a pivotal clinical study of its nanosecond Pulsed Field Ablation Cardiac Surgery System for atrial fibrillation. This FDA milestone highlights growing interest in nonthermal ablation technologies, which may reduce risks of collateral tissue damage compared to traditional methods. We’ll explore how FDA approval for the NANOCLAMP AF study could reshape...

Thinking about whether you should buy, hold, or cash out of AbbVie? You’re not alone. This stock has been anything but quiet lately, with its price closing at $218.34. Over just the last week, AbbVie jumped 4.1%, stacking on top of a solid 5.6% gain over the last month. Stretch that timeline out and AbbVie's numbers become even more impressive, with a 21.7% return year-to-date and nearly 200% over five years. These are the kinds of figures that tend to turn heads. What’s driving this surge in...

There has been a noticeable buzz around Waste Management (WM) lately, and it is not just about tidy neighborhoods. Recent analyst estimate revisions, paired with moderate investor optimism, have put WM squarely in the spotlight ahead of its upcoming earnings release. Solid earnings and revenue projections are making investors wonder if the company’s steady performance and growing dividend profile could make it a dependable pick in the current climate. If you zoom out beyond the weekly...

If you have been following IBEX (NasdaqGM:IBEX), this past week has been hard to ignore. The company just announced record fourth quarter and full year results, pushing the limits of what investors had come to expect. What is really sparking conversations is not only the headline growth, but the concrete shift from AI “proof of concept” to full-scale real-world deployments through its Wave iX platform. This, combined with the company’s move into the government sector and a major share...

Take a look at Altice USA’s stock chart and you might find yourself wondering if this is a classic turnaround story or just a value trap in disguise. After years of tough sledding, with the stock down more than 90.8% over five years and still off by 70.8% over a three-year window, the latest numbers offer hints of a pulse. Over the past week, Altice shares have ticked up by 6.2%, and they are modestly positive for the year so far at 0.8%. That is not headline-grabbing growth, but it signals...